Science (New York, N.Y.) · 2021
Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Reynolds Catherine J, Gibbons Joseph M, Pade Corinna, Lin Kai-Min, Sandoval Diana Muñoz, Pieper Franziska, Butler David K, Liu Siyi, Otter Ashley D, Joy George, Menacho Katia, Fontana Marianna, Smit Angelique, Kele Beatrix, Cutino-Moguel Teresa, Maini Mala K, Noursadeghi Mahdad, COVIDsortium Immune Correlates Network‡, Brooks Tim, Semper Amanda, Manisty Charlotte, Treibel Thomas A, Moon James C, COVIDsortium Investigators‡, McKnight Áine, Altmann Daniel M, Boyton Rosemary J
Аннотация
The impact of the initial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infecting strain on downstream immunity to heterologous variants of concern (VOCs) is unknown. Studying a longitudinal healthcare worker cohort, we found that after three antigen exposures (infection plus two vaccine doses), S1 antibody, memory B cells, and heterologous neutralization of B.1.351, P.1, and B.1.617.2 plateaued, whereas B.1.1.7 neutralization and spike T cell responses increased. Serology using the Wuhan Hu-1 spike receptor binding domain poorly predicted neutralizing immunity against VOCs. Neutralization potency against VOCs changed with heterologous virus encounter and number of antigen exposures. Neutralization potency fell differentially depending on targeted VOCs over the 5 months from the second vaccine dose. Heterologous combinations of spike encountered during infection and vaccination shape subsequent cross-protection against VOC, with implications for future-proof next-generation vaccines.
Предметные рубрики MeSH
AdultAntibodies, NeutralizingAntibodies, ViralAntigens, ViralBNT162 VaccineCOVID-19COVID-19 VaccinesCoronavirus Nucleocapsid ProteinsCross ProtectionFemaleHealth PersonnelHumansLongitudinal StudiesMaleMemory B CellsMutationPhosphoproteinsProtein DomainsSARS-CoV-2Spike Glycoprotein, CoronavirusT-LymphocytesVaccinationVaccine PotencyBreakthrough Infections